When comparing TMS in private mental health programs, ask what diagnosis is being treated, which device and protocol will be used, and who will manage the wider care plan. Transcranial magnetic stimulation is a clinical intervention with evidence for particular uses. Its presence on a residential program’s therapy menu does not establish suitability, superiority, or a guaranteed result.
For international patients, the decision also involves the length of stay, missed-session arrangements, access to the same treatment at home, and follow-up if symptoms return. A shorter advertised schedule may change travel requirements, but it does not remove the need for assessment and continuing care.
What TMS does, and how it differs from other procedures
Repetitive transcranial magnetic stimulation, usually shortened to rTMS, uses a coil near the scalp to deliver magnetic pulses that stimulate targeted brain regions. The US National Institute of Mental Health describes it as a noninvasive treatment. It is different from electroconvulsive therapy, which intentionally induces a seizure under anesthesia, and from surgically implanted brain stimulation.
A patient generally remains awake during rTMS. Treatment is delivered in repeated sessions, with the schedule depending on the protocol. “TMS,” “deep TMS,” and “theta-burst stimulation” are not interchangeable descriptions of one standardized package. The clinician should explain which approach is proposed and why it fits the clinical question.
This article concerns evaluating a service, not selecting stimulation settings. Decisions about target, intensity, session pattern, and medication coordination require trained clinical oversight.
Begin with the diagnosis and previous treatment
A useful assessment asks whether the symptoms represent unipolar depression, bipolar illness, OCD, another condition, or a combination. It reviews previous medication and psychological treatments, whether they were completed adequately, and what happened. A history described only as “nothing has worked” may conceal important differences between nonresponse, side effects, interrupted care, and an incorrect diagnosis.
The NHS depression treatment overview places treatment choices within a broader clinical plan. TMS should be compared with reasonable alternatives for the particular person, including further psychological or medication approaches and, in some circumstances, other specialist treatments.
Ask the assessor to state the intended goal. Is the proposal to reduce persistent depressive symptoms, improve functioning, or address a specifically authorized OCD indication? General promises to improve “brain performance” or treat every form of distress do not answer that question.
Read the regulatory claim precisely
In the United States, a device may be cleared for a specific indication and patient group. The FDA’s rTMS device guidance illustrates how intended use and safety requirements are tied to the device category. A general statement that a clinic uses “FDA technology” does not establish that its proposed use matches the device’s authorization.
For example, the FDA’s authorization of a deep TMS system for OCD concerns a particular treatment context. It should not be generalized to all machines, all protocols, or all anxiety disorders.
Outside the United States, ask about the relevant local device authorization and professional requirements. US clearance does not itself authorize a clinician to practice in another jurisdiction. Request the device name and the precise intended use in the written proposal, then ask the treating clinician to explain any use outside that authorization.
Understand what the evidence does and does not show
NICE guidance on rTMS for depression considers short-term efficacy evidence adequate while recognizing that clinical response varies. It emphasizes governance, consent, and audit, and encourages further evidence on patient selection, stimulation methods, maintenance, and longer-term outcomes. The guidance was moved from its former interventional-procedures number to HealthTech guidance without changing the recommendations.
This supports a more useful question than “Does TMS work?” Ask how evidence from the proposed protocol applies to people with a similar diagnosis and treatment history. A study of carefully selected adults with treatment-resistant depression cannot automatically predict results for a person with active substance dependence, bipolar symptoms, or another main condition.
Ask the clinic to distinguish response from remission, immediate improvement from sustained improvement, and trial findings from its own results. Our guide to evaluating outcome claims explains these distinctions in more detail.
Compare standard and accelerated schedules carefully
Some rTMS courses involve repeated weekday attendance across several weeks; accelerated approaches deliver multiple sessions within a shorter period. The number of sessions, spacing, targeting method, and total stimulation differ. A five-day label alone does not identify a specific research protocol.
Stanford’s report of a controlled accelerated-treatment study describes a defined intervention studied in a small group of people with treatment-resistant depression. Such findings can justify further clinical interest without proving that any clinic offering rapid TMS will reproduce the same results.
Ask whether the proposed service uses the same device, targeting approach, session schedule, and eligibility criteria as the evidence it cites. If it differs, the clinician should explain the evidence for that variation. Avoid choosing an accelerated schedule solely because it fits a holiday window or a fixed residential booking.
Safety screening should be specific
Tell the team about seizure history, neurological conditions, implanted devices or metal, pregnancy, medication changes, substance use, and major sleep disruption. The significance of each depends on the device and the individual assessment. Do not use a website checklist to decide eligibility yourself.
Oxford Health’s rTMS information describes screening concerns including epilepsy and metal near the head. Its side-effect information discusses discomfort and the small seizure risk. A service should explain both common effects and the plan for uncommon serious events without claiming that noninvasive means risk-free.
Ask who reviews changes during the course. If medication, alcohol use, sleep, or mood changes substantially, the stimulation team needs to know. The protocol should not continue automatically because the sessions have already been paid for. Hearing protection, device-specific procedures, and trained staff should be part of the discussion.
Look beyond the person operating the machine
Clarify who establishes the diagnosis, who prescribes the treatment, who performs sessions, and who reviews progress. These may be different people. Ask how they communicate and how a patient can reach a clinician if symptoms worsen between appointments.
In a residential program, establish whether TMS is delivered onsite or through an outside clinic. If outside, ask who arranges transport, shares records, coordinates medication changes, and handles missed sessions. A referral relationship can be workable, but it should be described accurately.
The wider treatment plan may include psychotherapy, medication, sleep support, and practical recovery goals. Our depression treatment abroad guide considers these choices, while medication management across services explains why one team needs to keep the overall picture in view.
Build a comparison around the actual offer
| Compare | Ask for |
|---|---|
| Clinical purpose | Diagnosis, intended benefit, and reasonable alternatives |
| Protocol | Device, targeting method, schedule, and evidence cited |
| Oversight | Responsible clinician, session staff, and review arrangements |
| Safety | Screening, side-effect monitoring, and emergency response |
| Outcomes | Measures used, assessment dates, and follow-up completeness |
| Continuity | Plan for incomplete response, relapse, or return home |
Use the same questions for each service. This makes differences visible without reducing the choice to machine branding or an unsupported league table.
Plan the period after the stimulation course
Ask when the treating clinician will assess the final response and what the next step will be if improvement is partial or absent. A person should not discover on the last day that the program has no plan beyond recommending another paid course.
If maintenance or repeat treatment is proposed, ask about the evidence, frequency, cost, and local availability. Do not assume a clinician at home can continue a specific protocol simply because TMS is offered somewhere in the home country. Transfer the relevant treatment record, including the protocol and clinical response, with consent.
The aftercare planning guide explains how to arrange a receiving clinician before departure. For someone already supported by a local psychiatrist, a joint discussion may clarify whether international travel adds useful access or creates avoidable discontinuity.
Measure changes that matter beyond the appointment
Alongside a symptom questionnaire, agree on a few everyday changes to discuss at review: getting out of bed, concentrating on a conversation, preparing meals, or resuming valued activities. These examples do not replace clinical measures; they help connect a numerical change with the person’s experience. If family observations are included, agree what may be shared and keep the patient’s own account central.
Ask how the service records deterioration as well as improvement. A useful review can change the plan when treatment is uncomfortable, ineffective, or no longer appropriate; it should not exist only to confirm that the purchased course is proceeding.
Calculate the complete cost and time commitment
Request an itemized proposal covering assessment, any imaging used for targeting, stimulation sessions, psychiatric reviews, accommodation, transport, and follow-up. Ask how missed sessions, early stopping, additional sessions, or a change in clinical recommendation affect the bill.
Check insurance for the exact indication, device-based treatment, clinician, and location. A policy covering depression treatment does not automatically cover every TMS protocol or treatment abroad. Allow for the possibility that assessment finds the intervention unsuitable; clarify financial terms before committing to a package.
A strong service can explain its evidence, limitations, and continuity plan in plain language. That explanation is more useful than a promise of rapid transformation and gives the patient a realistic basis for an informed decision with their treating clinician.